


SPECIAL FEATURES

Highlights of This Issue 1


CCR Translations

- 3 Ultrahigh Dose-rate Radiotherapy: Next Steps for FLASH-RT**
Kevin J. Harrington
See related article, p. 35
- 6 CDK4/6 Inhibitors: What Is the Best Cocktail?**
Marcos Malumbres
See related article, p. 403
- 9 Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy**
H. Kim Lyerly, Takuya Osada, and Zachary C. Hartman
See related article, p. 99

Reviews

- 12 Role of the RANK/RANKL Pathway in Multiple Myeloma**
 Noopur S. Raje, Sumita Bhatta, and Evangelos Terpos
- 21 To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity**
Malaka Ameratunga, Emma Kipps, Alicia F.C. Okines, and Juanita S. Lopez

CLINICAL TRIAL BRIEF REPORT

- 29 Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report**
 Xia Xiao, Xiaoyuan He, Qing Li, Huan Zhang, Juanxia Meng, Yanyu Jiang, Qi Deng, and Mingfeng Zhao
- 35 The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients**
Marie-Catherine Vozenin, Pauline De Fornel, Kristoffer Petersson, Vincent Favaudon, Maud Jaccard, Jean-François Germond, Benoit Petit, Marco Burki, Giséle Ferrand, David Patin, Hanan Bouchaab, Mahmut Ozsahin, François Bochud, Claude Bailat, Patrick Devauchelle, and Jean Bourhis
See related commentary, p. 3

CLINICAL TRIALS: TARGETED THERAPY

- 43 A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers**
Himisha Beltran, Clara Oromendia, Daniel C. Danila, Bruce Montgomery, Christopher Hoimes, Russell Z. Szmulewitz, Ulka Vaishampayan, Andrew J. Armstrong, Mark Stein, Jacek Pinski, Juan M. Mosquera, Verena Sailer, Rohan Bareja, Alessandro Romanel, Naveen Gumpeni, Andrea Sboner, Etienne Dardenne, Loredana Puca, Davide Prandi, Mark A. Rubin, Howard I. Scher, David S. Rickman, Francesca Demichelis, David M. Nanus, Karla V. Ballman, and Scott T. Tagawa
- 52 Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer**
Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary-Ellen Taplin, James Babb, Ethan S. Barnett, Alejandro Gomez-Pinillos, Xiaomei Liu, Dirk Moore, Robert DiPaola, and Tomasz M. Beer
- 64 Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers**
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H. Lam, Michael W. Lu, and Thomas E. Stinchcombe
- 73 Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma**
Jaishri O. Blakeley, Stuart A. Grossman, Andrew S. Chi, Tom Mikkelsen, Myrna R. Rosenfeld, Manmeet S. Ahluwalia, L. Burt Nabors, April Eichler, Ignacio Garcia Ribas, Serena Desideri, and Xiaobu Ye, on behalf of the Adult Brain Tumor Consortium



Table of Contents

- 80** **A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma**
Lipika Goyal, Hui Zheng, Thomas A. Abrams, Rebecca Miksad, Andrea J. Bullock, Jill N. Allen, Matthew B. Yurgelun, Jeffrey W. Clark, Avinash Kambadakone, Alona Muzikansky, Michelle Knowles, Aralee Galway, Anthony J. Afflitto, Caroline F. Dinicola, Eileen Regan, Tai Hato, Emilie Mamessier, Kohei Shigeta, Rakesh K. Jain, Dan G. Duda, and Andrew X. Zhu

- 90** **A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies**
Drew W. Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad, Anita K. Gandhi, Patrick R. Hagner, Yan Li, Xin Wei, Rajesh Chopra, Kristen Hege, Jorge DiMartino, and Kent Shih

CLINICAL TRIALS: IMMUNOTHERAPY

- 99** **First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors**
Julius Strauss, Christopher R. Heery, Joseph W. Kim, Caroline Jochems, Renee N. Donahue, Agnes S. Montgomery, Sheri McMahon, Elizabeth Lamping, Jennifer L. Marté, Ravi A. Madan, Marijo Bilusic, Matthew R. Silver, Elisa Bertotti, Jeffrey Schlom, and James L. Gulley
See related commentary, p. 9

- 110** **Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer**
Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow, Kimberly A. Kraynyak, Albert J. Sylvester, Dawson M. Knoblock, Joshua M. Bauml, Gregory S. Weinstein, Alexander Lin, Jean Boyer, Lindsay Sakata, Sophie Tan, Aubrey Anton, Kelsie Dickerson, Drishti Mangrolia, Russell Vang, Michael Dallas, Sandra Oyola, Susan Duff, Mark Esser, Rakesh Kumar, David Weiner, Ildiko Csiki, and Mark L. Bagarazzi

PRECISION MEDICINE AND IMAGING

- 125** **Intertumoral Heterogeneity of CD3⁺ and CD8⁺ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis**
Harry H. Yoon, Qian Shi, Erica N. Heying, Andrea Muranyi, Joerg Bredno, Faith Ough, Azita Djalilvand, June Clements, Rebecca Bowermaster, Wen-Wei Liu, Michael Barnes, Steven R. Alberts, Kandavel Shanmugam, and Frank A. Sinicrope

- 134** **Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer**
Pierre Laurent-Puig, Marie-Lise Grisoni, Volker Heinemann, François Liebaert, Daniel Neureiter, Andreas Jung, François Montestruc, Yann Gaston-Mathe, Raphaële Thiébaud, and Sebastian Stintzing

- 142** **A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment**
Meredith C. Henderson, Michael Silver, Quynh Tran, Elias E. Letsios, Rao Mulpuri, David E. Reese, Ana P. Lourenco, Joshua LaBaer, Karen S. Anderson, Josie Alpers, Carrie Costantini, Nitin Rohatgi, Haythem Ali, Karen Baker, Donald W. Northfelt, Karthik Ghosh, Stephen R. Grobmyer, Winnie Polen, and Judith K. Wolf

- 150** **Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer**
Yang Xie, Wei Lu, Shidan Wang, Ximing Tang, Hao Tang, Yunyun Zhou, Cesar Moran, Carmen Behrens, Jack A. Roth, Qinghua Zhou, David H. Johnson, Stephen G. Swisher, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Guanghua Xiao, John D. Minna, and Ignacio I. Wistuba

- 158** **Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer**
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y. Yeap, Chiara Ambrogio, Lorin A. Ferris, Christine Lydon, Tom Nguyen, Nicholas A. Jessop, A. John Iafrate, Bruce E. Johnson, Jochen K. Lennerz, Alice T. Shaw, and Mark M. Awad

- 166** **A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer**
Kelly E. Henry, Megan M. Dacek, Thomas R. Dilling, Jonathan D. Caen, Ian L. Fox, Michael J. Evans, and Jason S. Lewis

- 177** **Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer**
Sumith A. Kularatne, Mini Thomas, Carrie H. Myers, Pravin Gagare, Ananda K. Kanduluru, Christa J. Crihan, and Brandy N. Cichocki

Table of Contents

188 Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models

Mo Zhang, Naoko Kobayashi, Kirstin A. Zettlitz, Evelyn A. Kono, Joyce M. Yamashiro, Wen-Ting K. Tsai, Ziyue K. Jiang, Chau P. Tran, Chung Wang, Johnny Guan, Anna M. Wu, and Robert E. Reiter

201 Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia

Mu Hao, Bart Barlogie, Guido Tricot, Lanting Liu, Lugui Qiu, John D. Shaughnessy Jr, and Fenghuang Zhan

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

210 Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target

Vadim S. Koshkin, Jorge A. Garcia, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse K. McKenney, Kumiko Isse, Evan Bishop, Laura R. Saunders, Aysegul Balyimez, Summya Rashid, Ming Hu, Andrew J. Stephenson, Amr F. Fergany, Byron H. Lee, Georges-Pascal Haber, Afshin Dowlati, Timothy Gilligan, Moshe C. Ornstein, Brian I. Rini, Mohamed E. Abazeed, Omar Y. Mian, and Petros Grivas

222 USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia

Qi Jin, Carlos A. Martinez, Kelly M. Arcipowski, Yixing Zhu, Blanca T. Gutierrez-Diaz, Kenneth K. Wang, Megan R. Johnson, Andrew G. Volk, Feng Wang, Jian Wu, Charles Grove, Hui Wang, Ivan Sokirniy, Paul M. Thomas, Young Ah Goo, Nebiyu A. Abshiru, Nobuko Hijjiya, Sofie Peirs, Niels Vandamme, Geert Bex, Steven Goosens, Stacy A. Marshall, Emily J. Rendleman, Yoh-hei Takahashi, Lu Wang, Radhika Rawat, Elizabeth T. Bartom, Clayton K. Collings, Pieter Van Vlierberghe, Alexandros Strikoudis, Stephen Kelly, Beatrix Ueberheide, Christine Mantis, Irawati Kandela, Jean-Pierre Bourquin, Beat Bornhauser, Valentina Serafin, Silvia Bresolin, Maddalena Paganin, Benedetta Accordi, Giuseppe Basso, Neil L. Kelleher, Joseph Weinstock, Suresh Kumar, John D. Crispino, Ali Shilatfard, and Panagiotis Ntziachristos

240 The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival

Saskia J. Santeagoets, Vanessa J. van Ham, Iлина Ehsan, Pompimol Charoentong, Chantal L. Duurland, Vincent van Unen, Thomas Höllt, Lilly-Ann van der Velden, Sylvia L. van Egmond, Kim E. Kortekaas, Peggy J. de Vos van Steenwijk, Mariëtte I.E. van Poelgeest, Marij J.P. Welters, and Sjoerd H. van der Burg

253 Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib

Anne Berberich, Tobias Kessler, Carina M. Thomé, Stefan Pusch, Thomas Hielscher, Felix Sahm, Iris Oezen, Lara-Marie Schmitt, Sara Ciprut, Nanina Hucke, Petra Ruebmann, Manuel Fischer, Dieter Lemke, Michael O. Breckwoldt, Andreas von Deimling, Martin Bendszus, Michael Platten, and Wolfgang Wick

266 Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients

Daniela Osti, Massimiliano Del Bene, Germana Rappa, Mark Santos, Vittoria Matafora, Cristina Richichi, Stefania Faletti, Galina V. Beznoussenko, Alexandre Mironov, Angela Bachi, Lorenzo Fornasari, Daniele Bongetta, Paolo Gaetani, Francesco DiMeco, Aurelio Loricco, and Giuliana Pelicci

277 Combined Blockade of Activating *ERBB2* Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric H. Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler Jr, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, and Carlos L. Arteaga

290 Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Carmela Passaro, Quazim Alayo, Isabella De Laura, John McNulty, Korneel Grauwet, Hirotaka Ito, Vivek Bhaskaran, Marco Mineo, Sean E. Lawler, Khalid Shah, Maria C. Speranza, William Goins, Eric McLaughlin, Soledad Fernandez, David A. Reardon, Gordon J. Freeman, E. Antonio Chiocca, and Hiroshi Nakashima




Table of Contents

- 300** **The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies**
Matthew C. Stubbs, Timothy C. Burn, Richard Sparks, Thomas Maduskuie, Sharon Diamond, Mark Rupar, Xiaoming Wen, Alla Volgina, Nina Zolotarjova, Paul Waeltz, Margaret Favata, Ravi Jalluri, Huiqing Liu, Xuesong Mike Liu, Jun Li, Robert Collins, Nikoo Falahatpisheh, Padmaja Polam, Darlise DiMatteo, Patricia Feldman, Valerie Dostalík, Pramod Thekkat, Christine Gardiner, Xin He, Yanlong Li, Maryanne Covington, Richard Wynn, Bruce Ruggeri, Swamy Yeleswaram, Chu-Biao Xue, Wenqing Yao, Andrew P. Combs, Reid Huber, Gregory Hollis, Peggy Scherle, and Phillip C.C. Liu
- 312** **NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263**
Anahita Dastur, AHyun Choi, Carlotta Costa, Xunqin Yin, August Williams, Joseph McClanaghan, Max Greenberg, Justine Roderick, Neha U. Patel, Jessica Boisvert, Ultan McDermott, Mathew J. Garnett, Jorge Almenara, Steven Grant, Kathryn Rizzo, Jeffrey A. Engelman, Michelle Kelliher, Anthony C. Faber, and Cyril H. Benes
- 325** **Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma**
Wesley E. Barry, Jeremy R. Jackson, Grace E. Asuelime, Hong-Wei Wu, Jianping Sun, Zesheng Wan, Jemily Malvar, Michael A. Sheard, Larry Wang, Robert C. Seeger, and Eugene S. Kim
- 334** **PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma**
Frederik Holst, Henrica M.J. Werner, Siv Mjøs, Erling A. Hoivik, Kanthida Kusonmano, Elisabeth Wik, Anna Berg, Even Birkeland, William J. Gibson, Mari K. Halle, Jone Trovik, Andrew D. Cherniack, Karl-Henning Kalland, Gordon B. Mills, Christian F. Singer, Camilla Krakstad, Rameen Beroukhi, and Helga B. Salvesen
- 346** **Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers**
Carl M. Gay, Pan Tong, Robert J. Cardnell, Triparna Sen, Xiao Su, Jun Ma, Rasha O. Bara, Faye M. Johnson, Chris Wakefield, John V. Heymach, Jing Wang, and Lauren A. Byers
- 358** **Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts**
Carter M. Suryadevara, Rupen Desai, S. Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, David J. Snyder, James E. Herndon II, Patrick Healy, Elizabeth A. Reap, Gary E. Archer, Peter E. Fecci, John H. Sampson, and Luis Sanchez-Perez
- 369** **Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia**
Na Li, Michael A. Lopez, Maria Linares, Subodh Kumar, Stefania Oliva, Joaquin Martinez-Lopez, Lian Xu, Yan Xu, Tommaso Perini, William Senapedis, Erkan Baloglu, Masood A. Shammas, Zachary Hunter, Kenneth C. Anderson, Steven P. Treon, Nikhil C. Munshi, and Mariateresa Fulciniti
- 378** **Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability–High Colorectal Cancers**
Kazuhiro Sato, Masahito Kawazu, Yoko Yamamoto, Toshihide Ueno, Shinya Kojima, Genta Nagae, Hiroyuki Abe, Manabu Soda, Takafumi Oga, Shinji Kohsaka, Eirin Sai, Yoshihiro Yamashita, Hisae Inuma, Masashi Fukayama, Hiroyuki Aburatani, Toshiaki Watanabe, and Hiroyuki Mano
- 390** **CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status**
Carolina Rubio, Mónica Martínez-Fernández, Cristina Segovia, Iris Lodewijk, Cristian Suarez-Cabrera, Carmen Segrelles, Fernando López-Calderón, Ester Munera-Maravilla, Mirentxu Santos, Alejandra Bernardini, Ramón García-Escudero, Corina Lorz, María José Gómez-Rodríguez, Guillermo de Velasco, Irene Otero, Felipe Villacampa, Felix Guerrero-Ramos, Sergio Ruiz, Federico de la Rosa, Sara Domínguez-Rodríguez, Francisco X. Real, Núria Malats, Daniel Castellano, Marta Dueñas, and Jesus M. Paramio
- 403** **Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma**
Xinhua Song, Xianqiong Liu, Haichuan Wang, Jingxiao Wang, Yu Qiao, Antonio Cigliano, Kirsten Utpatel, Silvia Ribback, Maria G. Pilo, Marina Serra, John D. Gordan, Li Che, Shanshan Zhang, Antonio Cossu, Alberto Porcu, Rosa M. Pascale, Frank Dombrowski, Hongbo Hu, Diego F. Calvisi, Matthias Evert, and Xin Chen
See related commentary, p. 6

Table of Contents

- 414** Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth
Young Shin Song, Min Joo Kim, Hyun Jin Sun, Hwan Hee Kim, Hyo Shik Shin, Young A. Kim, Byung-Chul Oh, Sun Wook Cho, and Young Joo Park


- 426** Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer
 Elahe A. Mostaghel, Ailin Zhang, Susana Hernandez, Brett T. Marck, Xiaotun Zhang, Daniel Tamae, Heather E. Biehl, Maria Tretiakova, Jon Bartlett, John Burns, Ruth Dumpit, Lisa Ang, Alvin M. Matsumoto, Trevor M. Penning, Steven P. Balk, Colm Morrissey, Eva Corey, Lawrence D. True, and Peter S. Nelson

- 440** Acknowledgment to Reviewers

 AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows patient-derived organoids from a liver biopsy of a patient with neuroendocrine prostate cancer. For details, see manuscript by Beltran and colleagues on page 43 of this issue.



Clinical Cancer Research

25 (1)

Clin Cancer Res 2019;25:1-450.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/25/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/25/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.